Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet - Novo Nordisk (NYSE:NVO)
Novo Nordisk said the UK MHRA approved an oral Wegovy tablet containing semaglutide, offering a non-injectable GLP-1 option for adults with obesity (BMI≥30) or overweight (BMI 27–<30) with weight-related conditions, alongside diet and exercise. The Phase 3 OASIS 4 trial reported ~13.6% vs 2.4% weight loss after 64 weeks (adherence: ~16.6% vs 2.7%). GI events were most common; launch is planned for 2H 2026.
UK regulatory approval of oral Wegovy is a meaningful product milestone that can broaden addressable demand versus injectable-only GLP-1 weight-loss therapy.
MHRA approved Novo Nordisk’s oral Wegovy (semaglutide) tablet, expanding its obesity treatment options and supporting a 2026 commercial launch plan.
Likely near-term positive bias for NVO as the market prices in incremental sales potential and reduced administration friction; follow-through depends on launch execution and uptake.
Background
Wegovy is Novo Nordisk’s semaglutide-based obesity therapy; this is the first UK approval for an oral (non-injectable) tablet option.
Why it matters
Regulatory clearance in the UK expands the product’s route-of-administration and can broaden the eligible patient pool, supporting incremental revenue expectations ahead of a planned 2H 2026 launch in select markets.
Market relevance
A fresh UK regulatory approval with Phase 3 efficacy/safety data and a stated 2026 launch plan is a direct catalyst for NVO’s obesity franchise outlook.
Market effects
Strengthens the competitive narrative for oral GLP-1 weight-loss formulations, potentially raising expectations for oral delivery pipelines across the GLP-1 obesity space.
UK approval (MHRA) can accelerate adoption in Europe and may shift payer/physician preferences toward oral semaglutide where available.
Adds a third regulator approval (after FDA and UAE), reinforcing global commercialization momentum and reducing regulatory overhang risk.
Alternative perspectives
Oral convenience may not translate into proportionally higher demand if pricing, reimbursement, or tolerability limits uptake versus injectables.
The article excludes diabetic patients in the Phase 3 description and provides GI adverse-event rates; traders may need to monitor real-world discontinuation, formulary access, and manufacturing/launch capacity into 2H 2026.
Key entities
- companyNovo Nordisk
Company receiving MHRA approval for oral Wegovy tablets containing semaglutide.
- regulatorMHRA
UK medicines regulator that cleared the oral Wegovy option.
- clinical_trialOASIS 4
Phase 3 trial supporting efficacy and safety for oral semaglutide tablets in obesity/overweight adults excluding diabetes.
